Ginkgo Bioworks

American biotechnology company
Ginkgo Bioworks Holdings, Inc.
Ginkgo Bioworks logo.svg
TypePublic company
Traded as
  • Russell 1000 component
Founded2009; 13 years ago (2009) in Boston, Massachusetts, U.S.
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Boston, Massachusetts
Key people
  • Tom Knight
  • Jason Kelly
  • Reshma Shetty
  • Barry Canton
  • Austin Che
  • Christina Agapakis
RevenueIncrease US$313.84 million (2021)[1]
Decrease US$−1.83 billion (2021)[1]
Net income
Decrease US$−1.83 billion (2021)[1]
Total assetsIncrease US$2.07 billion (2021)[1]
Total equityIncrease US$1.57 billion (2021)[1]
Number of employees
641 (Dec 2021)[1]

Ginkgo Bioworks is an American biotech company founded in 2009 by scientists from MIT and headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications.[2][3][4][5] Ginkgo Bioworks is an analytics company that designs microorganisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and was one of the world's largest privately held biotech companies,[6] valued at $4.2 billion in 2019.[7] It raised $290 million in September and $350 million in October of that year.[6]


On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.[8] On 14 May 2021, Ginkgo announced its new ticker for the NYSE will be DNA. The ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche.[9] Trading began on September 17, 2021.[10][11] The investment management firm Baillie Gifford became the largest shareholder (15%) with the purchase of 167.75 million shares on 31 March 2022.[12]

In July 2022, Ginkgo Bioworks agreed to acquire Zymergen for $300 million in an all-stock deal.[13]

See also


  1. ^ a b c d e f "Ginkgo Bioworks Holdings, Inc. 2021 Form 10-K Report". U.S. Securities and Exchange Commission. 29 March 2022.
  2. ^ Molteni, Megan (14 September 2017). "With Designer Bacteria, Crops One Day Could Fertilize Themselves". Wired. Retrieved 4 December 2017.
  3. ^ Herper, Mathew (8 June 2016). "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry". Forbes. Retrieved 4 December 2017.
  4. ^ Adams, Susan (14 September 2017). "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer". Forbes. Retrieved 4 December 2017.
  5. ^ Weisman, Robert (29 September 2016). "Ginkgo Bioworks opens production site for custom cells". Boston Globe. Retrieved 4 December 2017.
  6. ^ a b "Ginkgo Bioworks raises $350 million fund for biotech spinouts". Reuters. 2019-10-09. Retrieved 2019-11-07.
  7. ^ "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods". Bloomberg. 6 November 2019. Retrieved 2019-11-07.
  8. ^ Hussain, Niket Nishant, Noor Zainab (2021-05-11). "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal". Reuters. Retrieved 2021-05-12.
  9. ^ Ginkgo Bioworks, Austin, Barry, Jason, Reshma, and Tom (14 May 2021). "Taking Ginkgo Public on NYSE:DNA". Ginkgo Bioworks. Ginkgo Bioworks. Retrieved 15 May 2021.
  10. ^ Leon, Riley (17 September 2021). "Ginkgo Bioworks begins trading on the NYSE after completing SPAC merger". CNBC. Retrieved 17 September 2021.
  11. ^ "Ginkgo Bioworks to Go Public with Over $1.6 Billion in Proceeds" (Press release). Business Wire. September 14, 2021.
  12. ^ "Baillie Gifford Just Bought Ginkgo Bioworks (DNA) Stock. Here's Why". 7 April 2022.
  13. ^ Saul, Derek (25 July 2022). "Ginkgo Buys Embattled Biotech Firm Zymergen For Paltry $300 Million". Forbes. Archived from the original on 26 July 2022.

External links

  • Official website
  • Business data for Ginkgo Bioworks Holdings, Inc.:
    • Bloomberg
    • Google
    • Reuters
    • SEC filings
    • Yahoo!

  • v
  • t
  • e